Tesamorelin vs Sermorelin: How They Actually Differ

Tesamorelin and sermorelin are both growth-hormone-releasing hormone (GHRH) analogs — peptides that nudge your own pituitary to release growth hormone — so they get lumped together constantly. But the most important difference between them isn't pharmacological. It's regulatory, and it shapes everything else: how each is made, how much evidence stands behind it, and what you can honestly expect.

The headline difference: one is FDA-approved, one is compounded

Tesamorelin is an FDA-approved drug. It is sold as EGRIFTA SV, a growth-hormone-releasing factor analog approved in the United States in 2010, and its label indication is narrow and specific: the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy¹. The same label is explicit about two limits that off-label marketing tends to skip — it is not indicated for weight-loss management, and its long-term cardiovascular safety has not been established¹. (That weight-loss limitation matters because sermorelin is so often marketed for fat loss — we test that claim in sermorelin for weight loss: does it actually help?.)

Sermorelin has no such current approval. Its branded product, Geref, was a real FDA-approved medicine, but it was discontinued in the mid-to-late 2000s for commercial reasons, not safety ones. The practical consequence is large: every dose of sermorelin prescribed in the US today is compounded by a pharmacy, not dispensed as an FDA-approved finished drug. That does not make it illegitimate — compounding is legal and routine — but it does mean sermorelin sits a full evidentiary tier below a drug that still carries an active approval and a current label.

If you remember one thing from this comparison, make it this: “tesamorelin vs sermorelin” is, first and foremost, “an approved drug with a narrow indication versus a compounded peptide used off-label.”

Same mechanism, different molecules

Mechanistically the two are cousins. Both bind the GHRH receptor on the pituitary and stimulate your own pulsatile growth-hormone release — which then raises IGF-1 — rather than injecting growth hormone directly. Preserving that natural pulsatility is a genuine pharmacological selling point of the GHRH-analog approach¹⁰.

The molecules differ in length. Tesamorelin is a stabilized analog of the full GHRH(1-44) peptide¹⁰. Sermorelin is GHRH(1-29) — the shortest fragment that retains full GH-releasing activity¹². Same receptor, same downstream signal, different peptide. (A different kind of GH peptide entirely — ipamorelin — hits the ghrelin receptor, not GHRH; we draw that distinction in sermorelin vs ipamorelin.)

What the evidence actually shows

This is where the two drugs separate sharply.

Tesamorelin has a robust, modern, randomized-controlled-trial base. In its pivotal Phase III trial it significantly reduced visceral adipose tissue (VAT) — the deep abdominal fat around the organs — versus placebo in people with HIV-associated fat accumulation, while raising IGF-1 and improving lipids². A second pivotal RCT confirmed it, with VAT falling roughly 11% versus a slight rise on placebo over 26 weeks, alongside improved triglycerides³. The benefit is not permanent: when people stop, visceral fat returns, so the effect depends on continued dosing⁴. Beyond visceral fat, randomized data show tesamorelin reduces liver fat and slows fibrosis progression in HIV-associated fatty liver disease⁵, and its visceral-fat reduction tracks with an improved metabolic profile⁶ and lower inflammatory markers⁷ — even improving the “quality” of fat independent of how much is lost⁸. A systematic review of GH-axis treatments for HIV lipodystrophy puts tesamorelin's VAT efficacy on solid ground while flagging the class effects to watch⁹. (For a fuller accounting of what tesamorelin is and isn't proven to do, see tesamorelin benefits: what the evidence shows.)

Sermorelin's human evidence is thinner, older, and built on surrogate endpoints. The classic supporting study gave GHRH(1-29) as single nightly injections to healthy elderly men and showed it raised growth hormone and IGF-1¹² — a real finding, but a short, small, lab-marker study, not a trial of how people looked, felt, or performed. Sermorelin's other well-documented role is diagnostic: GHRH(1-29) was used as a provocative test of pituitary GH reserve¹³. What does not exist is a modern, large RCT showing sermorelin improves body composition or delivers “anti-aging” outcomes. So any claim that sermorelin builds muscle, strips fat, or reverses aging is extrapolation from “it raises GH and IGF-1 short-term,” not a proven result. We keep that distinction strict in our pillar guide to sermorelin's evidence and in our look at whether sermorelin builds muscle.

Safety and monitoring: shared class effects

Because both drugs work through the GH/IGF-1 axis, they share the same monitoring priorities: IGF-1 levels and glucose. Tesamorelin reliably raises IGF-1, and the systematic review and metabolic literature emphasize watching the GH/IGF-1 axis and glucose handling during treatment⁹¹¹. In its trials tesamorelin was generally well tolerated without large net glucose worsening, but — per its own label — long-term cardiovascular safety is not established, and it is not a weight-loss drug¹. Sermorelin, as a GHRH analog, carries the same class cautions in principle, but with far less controlled long-term human safety data behind it. Neither is a casual supplement.

Who each is actually for

Tesamorelin has a defined patient: adults with HIV-associated lipodystrophy and excess visceral fat, dosed at 2 mg subcutaneously once daily¹⁰ (now delivered as 1.4 mg of the reformulated EGRIFTA SV — we break that down in tesamorelin dosage: the 2 mg protocol explained). Outside that indication, it is off-label.

Sermorelin's historical role was as a pediatric growth-hormone-deficiency diagnostic and treatment agent¹³; today it is prescribed off-label and compounded, typically for adult “GH optimization,” wellness, sleep, or anti-aging goals — none of which is an FDA-approved use. The closest real controlled evidence for GHRH-class effects in aging comes from a trial of a GHRH analog in older adults that found cognitive effects alongside raised IGF-1¹⁴ — but that was investigational research, not an approval for either drug, and it does not license the marketing claims attached to compounded sermorelin. (Notably, that cognition trial used tesamorelin, not sermorelin — a distinction we unpack in sermorelin and cognition: can a GHRH peptide help the aging brain?.) For where sermorelin's aging claims hold up and where they don't, see is sermorelin really anti-aging?.

The bottom line

Tesamorelin and sermorelin engage the same pathway, but they live in different worlds. Tesamorelin is an FDA-approved drug with a narrow indication and a real Phase III trial record for reducing visceral and liver fat — and a label that openly limits what it is for. Sermorelin is a compounded, off-label GHRH peptide whose human evidence is largely old, small, and marker-based, with no modern outcome trials behind the body-composition and anti-aging claims made for it. If you are comparing them, compare the evidence honestly: robust-but-narrow versus plausible-but-unproven. (To bring a third GH peptide into the comparison, see sermorelin vs tesamorelin vs ipamorelin; for a different GHRH-side comparison — sermorelin against the longer-acting research peptide CJC-1295 — see sermorelin vs CJC-1295.) And because sermorelin is compounded, it shows up in needle-free forms — tablets, troches, sublingual drops — whose absorption is far weaker than the marketing implies; we dig into that in do oral and sublingual sermorelin actually work?. If you want to see how the providers offering sermorelin stack up on price and oversight, we rank them in our guide to the best sermorelin providers.